01. October 2020 | 13:25 CET
BioNTech, NEL ASA, BYD: Which shares will rise afterward?
In international comparison, BioNTech is one of the leading pharmaceutical companies in the fight against corona. The research team is receiving substantial funding and support from investors and government agencies for the development of a vaccine against Covid-19. NEL ASA is one of the pioneers in the hydrogen sector and is involved in the development of plant infrastructure for multiple projects. BYD is a company from China that trades as a future competitor of Tesla in investor circles. All companies have proven to be successful. Their share prices have reflected this success having multiplied drastically this year. This has resulted in several billion Euro market valuations. Once a vaccine against Covid-19 becomes available, one industry will benefit particularly and it offers an excellent entry scenario for investors.
time to read: 2 minutes by Mario Hose
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Total deceleration of everyday life
The spread of Covid-19 has brought many areas of everyday life to a standstill. During the particularly severe restrictions from March to May 2020, the streets were empty and air traffic significantly less. During this time, most people only bought their essentials. People felt vulnerable and restricted their consumption in fear of the unknown - or were forced to out of lack of choice.
Vaccinations are being prepared
Due to the efforts being made by biotechnology companies such as BioNTech, CureVac, and Sanofi to bring a vaccine against Covid-19 to market maturity, it is expected that vaccinations can be started in the first quarter of 2021 at the latest. As BioNTech alone is aiming for a production volume of up to one billion vaccine doses per year, it can be assumed that by 2022 at the latest all people - who so desire - will have been vaccinated.
Vaccination record as a voluntary mandatory document
Once a vaccine against COVID-19 is available, politics and the economy can begin returning to normal. Those who are vaccinated are likely to gain more freedom than those who reject its use due to the obvious risk with non-vaccine takers. When entering a function or boarding a plane, people may in the future not only be asked for their identity card but also their vaccination record. Judging by past events this year, nothing can be ruled out and everything is possible.
Trading houses position themselves for a price increase
The experts from Citigroup and Goldman Sachs have announced their assessment of a winner of the Post Covid-19 period. This is an area that has been pushed aside and avoided by the capital market in recent months. The time has now come for industry experts and investors to position themselves for what is to come.
Be greedy when others are afraid
The analysts of the two financial institutions assume that the overcapacity of crude oil will be used up in 2021 and that the price per barrel will rise again to USD 60.00 or higher. The shares of oil companies are currently still at rock bottom and are attracting little attention. Now is a good time to consider buying shares of producers that are positioned in a legally secure space and prioritise environmental protection. It is important that the company was profitable and had low production costs before the Covid-19 pandemic.
Positive analyst opinion
The Canadian oil producer Saturn Oil & Gas is one such company. During 2019, the company was profitable and was able to report attractive growth rates in revenues. CEO John Jeffrey has already announced that the company will be looking at acquisitions to benefit from the current situation. In recent months, the situation has been correspondingly quiet. Investors in Saturn Oil & Gas may therefore benefit twice over. At CAD 0.10, the currently unheeded share is still trading well below the price of CAD 0.30 two years ago. In the period before Covid-19, the analysts of GBC Research gave a target price of 0.31 CAD in their buy recommendation - this would result in a highly attractive return.
